The evidence that kidney-specific knockout of TFEB has no detectable effects on kidney physiology (Figs. 1, 2) suggests that targeting TFEB could represent an alternative and potentially safer therapeutic strategy for TSC-associated renal disease, and potentially for other TSC-associated manifestations. This evidence concerns the gene TFEB and tuberous sclerosis.